- Home
- FWRG vs PHAT Comparison
FWRG vs PHAT Comparison
Compare FWRG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- PHAT
- Stock Information
- Founded
- FWRG 1983
- PHAT 2018
- Country
- FWRG United States
- PHAT United States
- Employees
- FWRG N/A
- PHAT N/A
- Industry
- FWRG Restaurants
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- PHAT Health Care
- Exchange
- FWRG Nasdaq
- PHAT Nasdaq
- Market Cap
- FWRG 970.4M
- PHAT 820.8M
- IPO Year
- FWRG 2021
- PHAT 2019
- Fundamental
- Price
- FWRG $18.59
- PHAT $12.34
- Analyst Decision
- FWRG Strong Buy
- PHAT Strong Buy
- Analyst Count
- FWRG 10
- PHAT 5
- Target Price
- FWRG $22.20
- PHAT $16.40
- AVG Volume (30 Days)
- FWRG 915.7K
- PHAT 1.1M
- Earning Date
- FWRG 08-05-2025
- PHAT 08-07-2025
- Dividend Yield
- FWRG N/A
- PHAT N/A
- EPS Growth
- FWRG N/A
- PHAT N/A
- EPS
- FWRG 0.06
- PHAT N/A
- Revenue
- FWRG $1,105,027,000.00
- PHAT $114,039,000.00
- Revenue This Year
- FWRG $22.06
- PHAT $207.52
- Revenue Next Year
- FWRG $16.21
- PHAT $96.46
- P/E Ratio
- FWRG $317.53
- PHAT N/A
- Revenue Growth
- FWRG 14.53
- PHAT 1049.82
- 52 Week Low
- FWRG $12.90
- PHAT $2.21
- 52 Week High
- FWRG $22.71
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- FWRG 56.44
- PHAT 68.51
- Support Level
- FWRG $18.27
- PHAT $11.25
- Resistance Level
- FWRG $19.39
- PHAT $12.96
- Average True Range (ATR)
- FWRG 0.63
- PHAT 0.73
- MACD
- FWRG -0.00
- PHAT 0.02
- Stochastic Oscillator
- FWRG 62.99
- PHAT 80.38
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.